Sol-Gel Technologies (SLGL) Research & Development (2017 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Research & Development came in at $2.8 million in Q1 2026, down 68.49% year-on-year from $8.8 million in Q1 2025, and down 22.27% on a QoQ basis from $3.6 million in Q4 2025.
Sol-Gel Technologies (SLGL) Research & Development (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 10 years of Research & Development data on file, last reported at $2.8 million in Q1 2026.
- On a quarterly basis, Research & Development fell 68.49% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $16.7 million, a 21.38% decrease from a year earlier, with the FY2025 full-year figure at $22.8 million, up 28.09% from the prior year.
- Research & Development for Q1 2026 stood at $2.8 million, down from $3.6 million in the prior quarter.
- Over the last five years, Research & Development for SLGL reached as high as $9.4 million in Q1 2023 and fell as low as $2.0 million in Q3 2022.
- Historically, Research & Development has averaged $4.7 million across 5 years, with a median of $4.6 million in 2025.
- Across the five-year window, Research & Development soared 132.21% in 2023 and slumped 68.49% in 2026, its largest moves.
- Year by year, Research & Development stood at $4.2 million in 2022, then fell by 1.09% to $4.2 million in 2023, then grew by 24.6% to $5.2 million in 2024, then sank by 31.04% to $3.6 million in 2025, then dropped by 22.27% to $2.8 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $2.8 million in Q1 2026, $3.6 million in Q4 2025, and $5.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Sol-Gel Technologies | 234.04 Mn | 223.91 Mn | - | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.79 Mn |
| Dec 31, 2025 | 3.58 Mn |
| Sep 30, 2025 | 5.73 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Mar 31, 2025 | 8.84 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Mar 31, 2024 | 5.35 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 4.67 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Mar 31, 2023 | 9.39 Mn |
| Dec 31, 2022 | 4.22 Mn |
| Sep 30, 2022 | 2.04 Mn |
| Jun 30, 2022 | 2.38 Mn |
| Mar 31, 2022 | 4.04 Mn |
| Dec 31, 2021 | 4.99 Mn |
| Sep 30, 2021 | 5.99 Mn |
| Jun 30, 2021 | 6.93 Mn |